Arthur Wai Sung, MD
Pulmonary Disease · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Offices
- 7
Offices
7 locations · Stanford Health Care · University Healthcare Alliance
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sung’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A73764 · Current
Licensed to practise in California · since 2001 · expires 2026-12-31 · New York Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$52,060
Medicare paid this office $52,060 for 313 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 117 | $16,952 | $103 |
| Critical care, first 30-74 minutes | 58 | $12,414 | $185 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $6,687 | $106 |
| Return visit (30+ min) | 42 | $4,279 | $78 |
| New patient visit (45+ min) | 28 | $3,978 | $142 |
See all 8 services
| Return visit (30+ min) | 117 | $16,952 | $103 |
| Critical care, first 30-74 minutes | 58 | $12,414 | $185 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $6,687 | $106 |
| Return visit (30+ min) | 42 | $4,279 | $78 |
| New patient visit (45+ min) | 28 | $3,978 | $142 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,171 | $155 |
| Long return visit (40+ min) | 12 | $1,372 | $106 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $1,081 | $83 |
Who their Medicare patients are
313 Original Medicare patients in 2024. Average age 77 · Under 65 5% · 85 and older 18% · Women 55% · Also on Medicaid 32% · Health risk score 2.25. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Coronary heart disease 48% · COPD 48% · Diabetes 40% · Heart failure 40% · Chronic kidney disease 38% · Atrial fibrillation 35% · Cancer 31% · Depression 23% · Stroke 19% · Dementia 15%.
The office billed $248,152, Medicare allowed $68,803 and paid $52,060; for 454 services of 20 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 313 | 454 | 77 | 2.25 | $248,152 | $52,060 |
| 2023 | 370 | 605 | 75 | 1.96 | $332,215 | $59,552 |
| 2022 | 455 | 786 | 74 | 2.10 | $528,594 | $80,605 |
| 2021 | 484 | 919 | 75 | 2.04 | $649,761 | $97,936 |
| 2020 | 412 | 841 | 73 | 2.19 | $538,557 | $77,981 |
| 2019 | 664 | 1,480 | 73 | 2.12 | $627,960 | $115,051 |
| 2018 | 535 | 1,247 | 73 | 2.05 | $430,315 | $84,101 |
| 2017 | 371 | 699 | 72 | 2.06 | $364,883 | $66,251 |
| 2016 | 274 | 569 | 74 | 2.03 | $393,500 | $55,257 |
| 2015 | 301 | 830 | 73 | 2.10 | $848,454 | $78,537 |
| 2014 | 276 | 811 | 72 | 2.06 | $834,548 | $69,912 |
| 2013 | 173 | 387 | 73 | 2.07 | $336,020 | $33,389 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 126 | $16,410 | $92 |
| Return visit (30+ min) | 130 | $13,462 | $86 |
| Critical care, first 30-74 minutes | 32 | $8,581 | $191 |
| New patient visit (45+ min) | 33 | $4,168 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $2,185 | $109 |
| New patient visit (60+ min) | 12 | $2,075 | $173 |
| Telehealth originating site facility fee | 32 | $876 | $21 |
2022: 12 services
| Return visit (30+ min) | 134 | $15,654 | $87 |
| Return visit (30+ min) | 115 | $12,128 | $84 |
| Critical care, first 30-74 minutes | 29 | $10,724 | $191 |
| New patient visit (45+ min) | 50 | $6,490 | $130 |
| New patient visit (45+ min) | 47 | $5,652 | $120 |
| Aspiration of fluid from chest cavity using imaging guidance | 30 | $4,175 | $99 |
| Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 1-2 lymph nodes | 17 | $3,407 | $200 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 32 | $2,303 | $66 |
| Aspiration of initial secretion of lung airway using an endoscope | 14 | $1,118 | $80 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $715 | $51 |
| Short return visit (20+ min) | 11 | $713 | $55 |
| Telehealth originating site facility fee | 29 | $654 | $20 |
2021: 15 services
| Return visit (30+ min) | 143 | $17,305 | $88 |
| Return visit (30+ min) | 114 | $15,057 | $92 |
| Critical care, first 30-74 minutes | 27 | $14,622 | $195 |
| New patient visit (45+ min) | 61 | $7,720 | $127 |
| New patient visit (45+ min) | 53 | $6,769 | $128 |
| Aspiration of fluid from chest cavity using imaging guidance | 30 | $6,355 | $101 |
| Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 1-2 lymph nodes | 30 | $6,043 | $201 |
| New patient visit (60+ min) | 11 | $1,914 | $174 |
| New patient visit (60+ min) | 12 | $1,778 | $148 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $1,706 | $100 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | $1,602 | $89 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 32 | $1,467 | $46 |
| Aspiration of initial secretion of lung airway using an endoscope | 17 | $1,123 | $66 |
| Short return visit (20+ min) | 13 | $836 | $60 |
| Telehealth originating site facility fee | 22 | $530 | $22 |
2020: 16 services
| Critical care, first 30-74 minutes | 30 | $13,839 | $201 |
| Return visit (30+ min) | 121 | $11,740 | $63 |
| Return visit (30+ min) | 88 | $8,801 | $67 |
| Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 1-2 lymph nodes | 24 | $5,156 | $206 |
| New patient visit (45+ min) | 48 | $5,079 | $106 |
| Aspiration of fluid from chest cavity using imaging guidance | 29 | $4,757 | $103 |
| New patient visit (45+ min) | 36 | $4,233 | $118 |
| Telephone medical discussion with physician, 21-30 minutes | 36 | $2,658 | $72 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 35 | $2,418 | $69 |
| Long return visit (40+ min) | 20 | $1,895 | $95 |
| New patient visit (60+ min) | 13 | $1,871 | $144 |
| Telephone medical discussion with physician, 21-30 minutes | 21 | $1,816 | $79 |
| New patient visit (60+ min) | 11 | $1,565 | $142 |
| Long return visit (40+ min) | 14 | $1,369 | $98 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $670 | $48 |
| Telehealth originating site facility fee | 15 | $382 | $21 |
2019: 22 services
| Critical care, first 30-74 minutes | 54 | $21,780 | $196 |
| Return visit (30+ min) | 159 | $15,167 | $66 |
| New patient visit (45+ min) | 92 | $10,495 | $114 |
| Return visit (30+ min) | 80 | $8,619 | $70 |
| New patient visit (45+ min) | 63 | $7,191 | $114 |
| Aspiration of fluid from chest cavity | 42 | $5,653 | $80 |
| Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 1-2 lymph nodes | 26 | $5,254 | $202 |
| New patient visit (60+ min) | 34 | $4,692 | $138 |
| Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 3 or more lymph nodes | 17 | $3,806 | $224 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $3,597 | $92 |
| Long return visit (40+ min) | 37 | $3,534 | $96 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 33 | $1,884 | $57 |
| New patient visit (60+ min) | 15 | $1,879 | $125 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,609 | $124 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 110 | $1,297 | $12 |
| Test to determine lung volumes using sensors | 98 | $1,086 | $11 |
| Short return visit (20+ min) | 22 | $1,068 | $46 |
| Test to examine how well the lungs exchange gases | 118 | $1,000 | $8 |
| New patient visit (30+ min) | 11 | $753 | $68 |
| Test to measure expiratory airflow and volume | 22 | $183 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 11 | $132 | $12 |
| Test to examine how well the lungs exchange gases | 15 | $125 | $8 |
2018: 26 services
| Return visit (30+ min) | 149 | $13,071 | $65 |
| New patient visit (45+ min) | 88 | $9,615 | $109 |
| Aspiration of fluid from chest cavity using imaging guidance | 44 | $7,330 | $98 |
| New patient visit (60+ min) | 47 | $6,912 | $147 |
| Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 1-2 lymph nodes | 33 | $6,458 | $196 |
| Long return visit (40+ min) | 39 | $3,989 | $100 |
| Return visit (30+ min) | 40 | $3,933 | $69 |
| New patient visit (45+ min) | 25 | $3,154 | $126 |
| Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 3 or more lymph nodes | 13 | $2,875 | $221 |
| Needle biopsy of windpipe cartilage, airway, and/or lung using an endoscope | 13 | $2,023 | $156 |
| New patient visit (60+ min) | 13 | $1,814 | $140 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 20 | $1,807 | $90 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 38 | $1,388 | $37 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,306 | $93 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 97 | $1,144 | $12 |
| Test to examine how well the lungs exchange gases | 106 | $886 | $8 |
| Exam of lung airways with diagnostic or therapeutic procedure on growths using an endoscope and ultrasound | 14 | $848 | $61 |
| Test to determine lung volumes using sensors | 72 | $792 | $11 |
| Short return visit (20+ min) | 12 | $538 | $45 |
| Test to examine how well the lungs exchange gases | 31 | $252 | $8 |
| Test to determine lung volumes using gas dilution or washout | 20 | $231 | $11 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 16 | $189 | $12 |
| Test to measure expiratory airflow and volume | 22 | $181 | $8 |
| Test to measure expiratory airflow and volume | 20 | $150 | $7 |
| Test to determine lung volumes using sensors | 13 | $144 | $11 |
| Exam of lung airways using an endoscope | 13 | $38 | $3 |
2017: 15 services
| New patient visit (60+ min) | 113 | $16,313 | $144 |
| Return visit (30+ min) | 109 | $9,336 | $67 |
| Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 1-2 lymph nodes | 35 | $7,094 | $197 |
| New patient visit (45+ min) | 46 | $5,057 | $110 |
| Aspiration of fluid from chest cavity using imaging guidance | 40 | $4,666 | $95 |
| Long return visit (40+ min) | 33 | $3,219 | $95 |
| New patient visit (60+ min) | 14 | $1,979 | $141 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 31 | $1,728 | $56 |
| Return visit (30+ min) | 12 | $1,205 | $75 |
| Short return visit (20+ min) | 22 | $1,187 | $46 |
| Exam of lung airways with diagnostic or therapeutic procedure on growths using an endoscope and ultrasound | 11 | $666 | $61 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 19 | $219 | $12 |
| Test to determine lung volumes using sensors | 18 | $195 | $11 |
| Test to examine how well the lungs exchange gases | 19 | $152 | $8 |
| Exam of lung airways using an endoscope | 15 | $41 | $3 |
2016: 13 services
| New patient visit (60+ min) | 69 | $9,595 | $139 |
| Return visit (30+ min) | 90 | $8,040 | $66 |
| Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 1-2 lymph nodes | 30 | $6,162 | $199 |
| New patient visit (45+ min) | 50 | $5,032 | $101 |
| Aspiration of fluid from chest cavity using imaging guidance | 25 | $3,562 | $91 |
| Long return visit (40+ min) | 33 | $3,270 | $96 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 16 | $1,991 | $124 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 38 | $1,811 | $48 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,701 | $121 |
| Biopsy of lung airway using an endoscope | 11 | $1,031 | $94 |
| Short return visit (20+ min) | 22 | $1,003 | $46 |
| Exam of lung airways with diagnostic or therapeutic procedure on growths using an endoscope and ultrasound | 14 | $842 | $60 |
| Exam of lung airways using an endoscope | 13 | $34 | $3 |
2015: 15 services
| Needle biopsy of windpipe cartilage, airway, and/or lung using an endoscope | 66 | $12,402 | $180 |
| New patient visit (45+ min) | 87 | $9,840 | $113 |
| Return visit (30+ min) | 90 | $8,217 | $68 |
| New patient visit (60+ min) | 44 | $6,344 | $144 |
| Aspiration of fluid from chest cavity using imaging guidance | 30 | $6,001 | $103 |
| Ultrasound of lung airways using an endoscope | 70 | $4,244 | $59 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 50 | $2,248 | $45 |
| Long return visit (40+ min) | 26 | $2,234 | $86 |
| Needle biopsy of lobe of lung using an endoscope, each additional lobe | 28 | $1,852 | $53 |
| Computer-assisted image-guided navigation of lung airways using an endoscope | 21 | $1,812 | $86 |
| Diagnostic exam of lung airway using an endoscope | 12 | $1,699 | $131 |
| Short return visit (20+ min) | 24 | $1,636 | $44 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 12 | $1,274 | $106 |
| Biopsy of lung airway using an endoscope | 13 | $952 | $73 |
| Exam of lung airways using an endoscope | 26 | $44 | $2 |
2014: 17 services
| Needle biopsy of windpipe cartilage, airway, and/or lung using an endoscope | 73 | $13,954 | $181 |
| Return visit (30+ min) | 106 | $8,863 | $66 |
| Ultrasound of lung airways using an endoscope | 67 | $4,127 | $60 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 31 | $3,301 | $103 |
| Diagnostic exam of lung airway using an endoscope | 17 | $3,015 | $131 |
| New patient visit (45+ min) | 25 | $2,890 | $116 |
| Aspiration of fluid from chest cavity using imaging guidance | 20 | $2,618 | $101 |
| New patient visit (30+ min) | 41 | $2,565 | $63 |
| Short return visit (20+ min) | 47 | $2,457 | $44 |
| Computer-assisted image-guided navigation of lung airways using an endoscope | 28 | $2,423 | $84 |
| Biopsy of lung airway using an endoscope | 16 | $1,802 | $113 |
| Needle biopsy of lobe of lung using an endoscope, each additional lobe | 27 | $1,527 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,473 | $61 |
| Aspiration of fluid from chest cavity | 15 | $1,374 | $76 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,339 | $122 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 45 | $1,289 | $28 |
| Exam of lung airways using an endoscope | 32 | $40 | $1 |
2013: 9 services
| Needle biopsy of windpipe cartilage, airway, and/or lung using an endoscope | 22 | $3,911 | $178 |
| Return visit (30+ min) | 36 | $2,570 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $2,520 | $60 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 16 | $2,417 | $127 |
| New patient visit (45+ min) | 19 | $1,874 | $99 |
| Short return visit (20+ min) | 15 | $1,332 | $58 |
| Short return visit (20+ min) | 25 | $1,012 | $35 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 22 | $829 | $30 |
| Ultrasound of lung airways using an endoscope | 13 | $774 | $60 |
Medicaid work
$362 in 2023
Medicaid paid $362 for 14 billed services this clinician did in 2023, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 14 | $362 |
| 2023 | 14 | 1 | 14 | $362 |
Drugs they prescribed that Part D paid
$128,433
Pharmacies billed $128,433 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 501) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
286 generic and 215 brand-name prescriptions · $128,433 in drug cost · 66 antibiotic prescriptions to 17 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Breztri Aerosphere | 38 | $29,121 | $766 |
| Trelegy Ellipta | 24 | $22,178 | $924 |
| Spiriva Handihaler | 17 | $14,285 | $840 |
| Combivent Respimat | 18 | $10,684 | $594 |
| Tiotropium | 24 | $10,256 | $427 |
See all 17 drugs
| Breztri Aerosphere | 38 | $29,121 | $766 |
| Trelegy Ellipta | 24 | $22,178 | $924 |
| Spiriva Handihaler | 17 | $14,285 | $840 |
| Combivent Respimat | 18 | $10,684 | $594 |
| Tiotropium | 24 | $10,256 | $427 |
| Symbicort | 23 | $5,370 | $233 |
| Breo Ellipta | 14 | $5,166 | $369 |
| Incruse Ellipta | 13 | $3,640 | $280 |
| Breyna | 15 | $3,549 | $237 |
| Wixela Inhub | 15 | $2,820 | $188 |
| Qvar Redihaler | 12 | $2,790 | $233 |
| Roflumilast | 32 | $2,432 | $76 |
| Azithromycin | 60 | $1,216 | $20 |
| Albuterol Sulfate Hfa | 24 | $784 | $33 |
| Prednisone | 56 | $684 | $12 |
| Montelukast | 23 | $654 | $28 |
| Azelastine | 11 | $164 | $15 |
Year by year
| 2024 | 501 | 92 | 0% (0) | 43% | $128,433 |
| 2023 | 547 | 89 | 0% (0) | 55% | $189,911 |
| 2022 | 598 | 103 | None | 65% | $206,578 |
| 2021 | 497 | 98 | None | 66% | $159,429 |
| 2020 | 485 | 105 | None | 67% | $168,272 |
| 2019 | 442 | 93 | None | 62% | $134,448 |
| 2018 | 278 | 66 | None | 67% | $75,758 |
| 2017 | 245 | 68 | None | 61% | $49,279 |
| 2016 | 213 | 59 | None | 66% | $40,158 |
| 2015 | 116 | 42 | None | 66% | $24,557 |
| 2014 | 58 | 22 | 0% (0) | 62% | $11,622 |
| 2013 | 219 | 49 | None | 73% | $39,322 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Spiriva Handihaler | 43 | $39,901 | $928 |
| Breztri Aerosphere | 31 | $24,863 | $802 |
| Symbicort | 33 | $19,375 | $587 |
| Advair Diskus | 23 | $17,412 | $757 |
| Trelegy Ellipta | 17 | $16,448 | $968 |
| Combivent Respimat | 22 | $14,357 | $653 |
| Spiriva Respimat | 21 | $11,913 | $567 |
| Incruse Ellipta | 30 | $11,726 | $391 |
| Breo Ellipta | 17 | $7,368 | $433 |
| Fluticasone-Salmeterol | 18 | $4,611 | $256 |
| Roflumilast | 23 | $3,315 | $144 |
| Flovent Hfa | 13 | $3,030 | $233 |
| Azithromycin | 56 | $2,403 | $43 |
| Wixela Inhub | 13 | $2,381 | $183 |
| Albuterol Sulfate Hfa | 50 | $1,501 | $30 |
| Ventolin Hfa | 13 | $1,172 | $90 |
| Montelukast | 22 | $795 | $36 |
| Prednisone | 52 | $571 | $11 |
2022: 16 drugs
| Spiriva Handihaler | 64 | $52,788 | $825 |
| Advair Diskus | 40 | $24,778 | $619 |
| Incruse Ellipta | 47 | $19,285 | $410 |
| Symbicort | 40 | $17,774 | $444 |
| Breo Ellipta | 31 | $13,605 | $439 |
| Breztri Aerosphere | 18 | $12,570 | $698 |
| Trelegy Ellipta | 14 | $12,085 | $863 |
| Combivent Respimat | 14 | $6,915 | $494 |
| Spiriva Respimat | 12 | $6,449 | $537 |
| Fluticasone-Salmeterol | 25 | $5,860 | $234 |
| Wixela Inhub | 17 | $4,927 | $290 |
| Albuterol Sulfate Hfa | 61 | $3,229 | $53 |
| Ventolin Hfa | 22 | $1,716 | $78 |
| Azithromycin | 35 | $1,170 | $33 |
| Montelukast | 25 | $769 | $31 |
| Prednisone | 55 | $488 | $9 |
2021: 12 drugs
| Spiriva | 63 | $44,889 | $713 |
| Advair Diskus | 36 | $22,990 | $639 |
| Symbicort | 41 | $19,730 | $481 |
| Incruse Ellipta | 32 | $14,981 | $468 |
| Breo Ellipta | 30 | $12,685 | $423 |
| Spiriva Respimat | 15 | $7,645 | $510 |
| Wixela Inhub | 24 | $6,596 | $275 |
| Albuterol Sulfate Hfa | 55 | $2,785 | $51 |
| Ventolin Hfa | 41 | $2,408 | $59 |
| Azithromycin | 21 | $949 | $45 |
| Prednisone | 52 | $475 | $9 |
| Montelukast | 15 | $341 | $23 |
2020: 12 drugs
| Spiriva | 65 | $47,300 | $728 |
| Advair Diskus | 37 | $25,013 | $676 |
| Symbicort | 37 | $20,801 | $562 |
| Incruse Ellipta | 42 | $17,262 | $411 |
| Breo Ellipta | 23 | $8,665 | $377 |
| Spiriva Respimat | 14 | $6,625 | $473 |
| Wixela Inhub | 16 | $4,019 | $251 |
| Albuterol Sulfate Hfa | 27 | $1,186 | $44 |
| Ventolin Hfa | 18 | $1,026 | $57 |
| Azithromycin | 17 | $947 | $56 |
| Montelukast | 28 | $432 | $15 |
| Prednisone | 37 | $295 | $8 |
2019: 10 drugs
| Spiriva | 55 | $42,165 | $767 |
| Advair Diskus | 59 | $29,986 | $508 |
| Symbicort | 40 | $19,266 | $482 |
| Incruse Ellipta | 14 | $5,411 | $387 |
| Wixela Inhub | 18 | $3,746 | $208 |
| Proair Hfa | 19 | $1,464 | $77 |
| Montelukast | 54 | $941 | $17 |
| Ventolin Hfa | 15 | $846 | $56 |
| Azithromycin | 16 | $628 | $39 |
| Prednisone | 44 | $405 | $9 |
2018: 9 drugs
| Advair Diskus | 75 | $38,417 | $512 |
| Spiriva | 38 | $18,755 | $494 |
| Incruse Ellipta | 18 | $5,830 | $324 |
| Symbicort | 13 | $4,343 | $334 |
| Ventolin Hfa | 18 | $987 | $55 |
| Proair Hfa | 11 | $946 | $86 |
| Montelukast | 24 | $272 | $11 |
| Prednisone | 24 | $136 | $6 |
| Omeprazole | 12 | $78 | $7 |
2017: 6 drugs
| Advair Diskus | 36 | $16,021 | $445 |
| Spiriva | 35 | $12,969 | $371 |
| Incruse Ellipta | 19 | $6,282 | $331 |
| Ventolin Hfa | 25 | $1,338 | $54 |
| Prednisone | 27 | $255 | $9 |
| Azithromycin | 19 | $233 | $12 |
2016: 6 drugs
| Spiriva | 32 | $12,544 | $392 |
| Advair Diskus | 20 | $8,355 | $418 |
| Symbicort | 17 | $4,997 | $294 |
| Incruse Ellipta | 17 | $4,825 | $284 |
| Ventolin Hfa | 24 | $1,233 | $51 |
| Prednisone | 29 | $205 | $7 |
2015: 4 drugs
| Spiriva | 24 | $11,206 | $467 |
| Advair Diskus | 15 | $5,410 | $361 |
| Proair Hfa | 14 | $1,215 | $87 |
| Prednisone | 13 | $114 | $9 |
2014: 1 drug
| Spiriva | 19 | $7,160 | $377 |
2013: 6 drugs
| Spiriva | 62 | $18,007 | $290 |
| Advair Diskus | 40 | $11,749 | $294 |
| Nexium | 14 | $2,925 | $209 |
| Proair Hfa | 13 | $610 | $47 |
| Fluticasone Propionate | 17 | $408 | $24 |
| Prednisone | 15 | $43 | $3 |
Money from drug and device companies
$212 in 2025
| 2025 | 1 | 5 | $124 | $212 |
| 2022 | 1 | 1 | None | $35 |
| 2020 | 1 | 1 | None | $125 |
| 2019 | 2 | 23 | $4,745 | $10,271 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Taiho Oncology | None | $212 | 5 payments
|
See all 5 published payments
| Taiho Oncology | Meals · 2025-04-30 | None | $8 |
| Taiho Oncology | Travel · 2025-04-30 | None | $35 |
| Taiho Oncology | Travel · 2025-04-30 | None | $35 |
| Taiho Oncology | Travel · 2025-04-30 | None | $10 |
| Taiho Oncology | Paid to speak or teach · 2025-03-29 | None | $124 |
See earlier years (2022, 2020, 2019)
2022: $35
| Intuitive Surgical | Da Vinci Surgical System | $35 | 1 payment
|
2020: $125
| GlaxoSmithKline | Trelegy Ellipta | $125 | 1 payment
|
2019: $10,271
| Olympus America | Olympus Bronchoscopes | $5,766 | 10 payments
|
| Olympus Corporation of the Americas | Olympus Bronchoscopes | $4,505 | 13 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Pulmonx Corporation · Lung Function Improvement After Bronchoscopic Lung Volume Reduction With Pulmonx Endobronchial Valves Used in Treatment of Emphysema · 2021 | Their institution | $5,540 |
| Pulmonx Corporation · Lung Function Improvement After Bronchoscopic Lung Volume Reduction With Pulmonx Endobronchial Valves Used in Treatment of Emphysema · 2019 | Their institution | $4,530 |
| Pulmonx Corporation · Lung Function Improvement After Bronchoscopic Lung Volume Reduction With Pulmonx Endobronchial Valves Used in Treatment of Emphysema · 2022 | Their institution | $4,173 |
| Pulmonx Corporation · Lung Function Improvement After Bronchoscopic Lung Volume Reduction With Pulmonx Endobronchial Valves Used in Treatment of Emphysema · 2020 | Their institution | $3,030 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 94.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1942297809
- Licence
- CA A73764California A73764: Current · expires 2026-12-31
- Trained
- New York Medical College, 1999
- Group
- Stanford Health Care · University Healthcare Alliance
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- NY 02809281
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Federal specialty code 207RC0200X (207RC0200X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2005-10-05
- NPI last updated
- 2024-05-08
- NPI record certified
- 2024-05-08
This is when the NPI record was last certified, not a medical board exam.